Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 2, 2024Frontiers in PharmacologyOpen Access

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLudan ZhangRGRui GeDPDeng Pan

Discussion

Loading...

Member takes

Overview

Analysis demonstrates improved survival rates with venetoclax and hypomethylating agents in MDS and CMML patients, indicating potential benefits.

Key Points

  • The combined treatment of venetoclax and hypomethylating agents significantly improved overall response rates in MDS and CMML patients.
  • VEN-HMA therapy resulted in a 73.7% overall response rate, surpassing the 59.4% achieved with monotherapy HYPO agents.
  • Data from 51 patients analyzed, illustrating longer median overall survival of 16 months for the VEN-HMA group compared to HMA monotherapy group results. Key adverse events occurred at similar rates between both treatment groups.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e6bea5b6db64358763eaefhttps://doi.org/10.3389/fphar.2024.1265840
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The introduction of hypomethylation agents and venetoclax into standard care for older patients with acute myeloid leukemia: A retrospective real-world analysis of feasibility, safety, and effectiveness from an outpatient hematology center.2026
  2. 2Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience2026
  3. 3Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database2026 · 2 citations
  4. 4Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study2026
  5. 5Real-World Outcomes of Hypomethylating Agents and Venetoclax Combination Therapy in AML and Myelodysplastic Syndrome in Pakistan2026 · 1 citations